Fmoc-Tranexamic acid

Fmoc-Tranexamic acid is a high-purity Fmoc-protected derivative of tranexamic acid, a clinically approved antifibrinolytic agent, widely utilized in peptide synthesis and bioconjugation research [6†L4-L9]. The rigid trans-cyclohexane ring in Fmoc-Tranexamic acid provides enhanced metabolic stability and conformational constraint, making it particularly valuable for the synthesis of protease-resistant peptides and peptidomimetics [6†L4-L9]. Additionally, Fmoc-Tranexamic acid serves as a protective group in peptide synthesis, enabling the selective modification of amino acids without interfering with other functional groups, and can be used to create bioconjugates for targeted drug delivery systems and diagnostic tools [6†L6-L9]. For researchers requiring a conformationally constrained, Fmoc-protected building block for peptide therapeutics or bioconjugation applications, Fmoc-Tranexamic acid delivers the quality, purity, and versatility demanded by modern pharmaceutical research .

Product Parameters

Product Advantages

1. Conformationally Constrained Rigid Scaffold

The trans-cyclohexane ring in Fmoc-Tranexamic acid positions the aminomethyl and carboxylic acid functionalities on opposite sides of the ring, creating a rigid, conformationally locked scaffold. This pre-organized structure reduces entropic penalties upon target binding and confers enhanced metabolic stability compared to linear analogues—properties widely exploited in the design of protease-resistant peptides and peptidomimetics .

2. Clinically Validated Tranexamic Acid Core

Fmoc-Tranexamic acid incorporates the core scaffold of tranexamic acid—a clinically approved antifibrinolytic agent used for decades in the treatment of excessive bleeding. This clinically validated core provides a well-characterized safety and pharmacokinetic profile, making Fmoc-Tranexamic acid an attractive building block for the development of peptide-based therapeutics with improved drug-like properties.

3. Fmoc Protection for Standard SPPS Compatibility

Fmoc-Tranexamic acid is fully compatible with standard Fmoc SPPS protocols used in automated and manual peptide synthesizers. The Fmoc protecting group is stable under acidic conditions but rapidly and cleanly removed by piperidine, enabling efficient peptide chain assembly with high coupling efficiency and minimal side-reactions.

4. Versatile Applications Across Peptide Research

Fmoc-Tranexamic acid serves multiple roles in peptide research: as a protective group in solid-phase peptide synthesis, as a building block for the synthesis of peptides and peptidomimetics, as a linker for bioconjugation enabling attachment of biomolecules to surfaces or other molecules, and as a scaffold for the development of protease-stable peptide therapeutics with enhanced metabolic stability.

5. High-Purity Material for Reproducible Research

Our Fmoc-Tranexamic acid meets the rigorous quality standards required for automated Fmoc SPPS and bioconjugation research, with documented purity ≥98% (HPLC and titration), precisely characterized melting point (186.0–190.0 °C), and identity confirmation via NMR—ensuring high coupling efficiency and reproducible synthesis outcomes.

FAQ

Q1: What is Fmoc-Tranexamic acid?

A: Fmoc-Tranexamic acid (trans-4-(Fmoc-aminomethyl)cyclohexane-1-carboxylic acid) is an Fmoc-protected derivative of the clinically approved antifibrinolytic agent tranexamic acid. It serves as a conformationally constrained building block for peptide synthesis, peptidomimetic design, and bioconjugation applications.

Q2: What is the advantage of the trans-cyclohexane ring in Fmoc-Tranexamic acid?

A: The trans-cyclohexane ring positions the aminomethyl and carboxylic acid functionalities on opposite sides of the ring, creating a rigid, conformationally locked scaffold. This pre-organized structure reduces entropic penalties upon target binding and confers enhanced metabolic stability—properties valuable for the design of protease-resistant peptides and peptide therapeutics.

Product Quality Assurance

Cosperpharm has established a comprehensive quality assurance system for Fmoc-Tranexamic acid that meets the rigorous expectations of research-grade and pharmaceutical intermediate applications:

Thorough analytical characterization. Each batch undergoes multi-technique analytical release testing: HPLC purity (≥98.0 area%), neutralization titration purity confirmation (≥98.0%), melting point verification (186.0–190.0 °C), appearance verification (white to almost white powder to crystal), and identity confirmation via NMR.

Full batch traceability with retention samples. From raw material procurement (tranexamic acid from qualified suppliers) through Fmoc protection, purification, drying, and final packaging, every step is fully documented and traceable. Each batch receives a unique lot number with sufficient retention samples maintained in accordance with Cosperpharm quality procedures.

Stability monitoring program. Cosperpharm conducts ongoing stability studies under recommended storage conditions (0–10 °C, under inert atmosphere). Stability summaries are updated regularly, with full data packages available to support customer research and regulatory submissions.

Documentation ready for research and regulatory use. Every shipment includes a Certificate of Analysis (COA) with batch-specific purity and characterization data, a Material Safety Data Sheet (SDS), and customs documentation for international delivery. For customers requiring extended documentation, Cosperpharm provides custom quality agreements upon request.

Customer-initiated quality audits. Qualified customers are welcome to audit Cosperpharm‘s manufacturing, quality control, and documentation facilities. Please contact our regulatory team to schedule an audit.

Contact Us

Ready to advance your peptide synthesis program with Fmoc-Tranexamic acid? Contact Cosperpharm today—our team is ready to provide quotes, share technical documentation, and discuss custom supply options tailored to your specific research requirements.